Opportunities
Search

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this NOFO supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this NOFO supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population s...

Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Survivorship Research Award addresses the relatively new and underfunded area of melanoma-specific survivorship by supporting a broad range of innovative and impactful research that has the intended outcome of improving the health and well-being of melanoma survivors, their families and/or their care partners in the near term. Proposed studies focusing exclusively on animal models or considering survival only without consideration of quality of life, overall health and/or function are not responsive to this funding opportunity. Distinctive Features: ·        The application must include at least one melanoma consumer collaborator, defined as a melanoma survivor, family member and/or care partner who can provide lived experience expertise to the research project team, or a melanoma-community supporting organization to support the planning, execution, and implementation of the proposed research. ·        Clinical trials are allowed.

Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Idea Award supports innovative, exploratory, high-risk/potentially high-reward research. Novelty and innovation are expected to be key aspects of the proposed project. By the end of the Idea Award funding period, the anticipated outcomes of successful efforts should establish proof of principle and obtain preliminary data to secure follow-on funding.Distinctive Features: • Preliminary data are discouraged. • After submitting the required pre-application, investigators must receive an invitation to submit a full application.

Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Focused Program Award – Rare Melanomas, supports a multidisciplinary research program of at least two, but not more than three, distinct but complementary research projects addressing an overarching question relevant to rare melanomas. Distinctive Features: ·          *Updated for FY26* Investigators must include at least one rare melanoma survivor or patient advocate as part of the project team who will provide advice and consultation throughout planning, implementation, and results dissemination to maximize research impact. ·        This is a partnering mechanism, requiring an Initiating Principal Investigator (PI) and at least one, but not more than two, Partnering PIs, see Figure 1.                    Each named PI is expected to be a Project Leader for one of the proposed research projects. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). ·        After submitting the required pre-application, investigators must receive an invitation to submit a full application.                    Only the Initiating PI will submit a pre-application. All PIs must submit full applications. The Partnering PI(s)’s application is an abbreviated package specific to their proposed research project. ·        Clinical trials are allowed.

Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Team Science Award supports a broad range of hypothesis-driven, multidisciplinary studies that have a short-term goal of advancing the state of the science in melanoma research and/or patient care. Team science is a synergistic effort that harnesses techniques, approaches and perspectives from multiple disciplines and/or therapeutic areas to address complex, multi-dimensional problems that will impact patient outcomes. Distinctive Features: ·        This funding mechanism requires multiple Principal Investigators (PIs). At least two and up to three PIs should partner to jointly design and execute a single research project; multi-institutional partnerships are encouraged. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). ·        Consumer Collaboration Option: Investigators are encouraged, but not required, to form collaborative relationships with the melanoma consumer community to maximize the impact and translatability of the research for the benefit of the intended community(ies). ·        After submitting the required pre-application, investigators must receive an invitation to submit a full application.       Only the Initiating PI will submit a pre-application. All PIs must submit full applications. The Partnering PI(s)’s application is an abbreviated package specific to their proposed research effort.

Summary: Supports the addition of independent, early career investigators (Scholars) who are no more than seven years from their initial faculty appointment to the Melanoma Research Program (MRP) Melanoma Academy. The Melanoma Academy is a unique, interactive virtual academy focused on bringing together established investigators and Scholars to develop a network of successful, highly productive melanoma researchers in a collaborative research and career development environment.Distinctive Features:This award mechanism focuses on both the Scholar’s research and career potential in the melanoma field.Scholars must designate a Career Guide. The Career Guide must have a track record of successful mentorship coupled with a strong record of funding and publications in melanoma.Preliminary data are not required.

Expected Outcome:The call for proposals aims to facilitate effective and non-discriminatory access to justice for all, and effective redress, including by electronic means (e-Justice), by promoting efficient civil, and criminal procedures, and by promoting and supporting the rights of all victims of crime as well as the procedural rights of suspects and accused persons in criminal proceedings.This biennial call for proposals, under the Access to justice specific objective, covers two priorities: E-justice priorityVictims’ rights and procedural rights priority This topic is covering the Victims' rights and procedural rights priority of the call for proposals for EU action grants to support transnational projects in the fields of e-Justice, victims’ rights and procedural rights under the Justice Programme (JUST).For further information about the call and its conditions, please see the call...

Scope:The call for proposals aims to facilitate effective and non-discriminatory access to justice for all, and effective redress, including by electronic means (e-Justice), by promoting efficient civil, and criminal procedures, and by promoting and supporting the rights of all victims of crime as well as the procedural rights of suspects and accused persons in criminal proceedings.This biennial call for proposals, under the Access to justice specific objective, covers two priorities: E-justice priorityVictims’ rights and procedural rights priority This topic is covering the E-Justice priority of the call for proposals for EU action grants to support transnational projects in the fields of e-Justice, victims’ rights and procedural rights under the Justice Programme (JUST).For further information about the call and its conditions, please see the call document

EU support to Stakeholders to improve measurement of food waste and help implement food waste prevention in their operations and organisation - 2026-2027

Buyer: Vereniging van Bos- en natuurterreineigenaren (VBNE) | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-15

Buyer: Gemeente Zoetermeer | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-15

Buyer: Porin kaupungin hankintapalvelut | Notice type: pin-rtl | Procedure: open | Contract: supplies | Deadline: 2026-10-15

Buyer: Centre Hospitalier de Cayenne "Andrée ROSEMON" | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-15

Buyer: GGD Zaanstreek-Waterland | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-15

Buyer: Rīgas valstspilsētas pašvaldības Pilsētas attīstības departaments | Notice type: cn-desg | Procedure: open | Contract: services | Deadline: 2026-10-15

Buyer: Avri | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-15

Buyer: Erasmus Universiteit Rotterdam | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-15

Buyer: AGV | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-15

Buyer: Miejski Zakład Komunikacyjny Sp. z o.o. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-15

Buyer: Port de Bruxelles | Notice type: cn-standard | Procedure: comp-dial | Contract: services | Deadline: 2026-10-15

NSF Astronomy and Astrophysics Postdoctoral Fellowships provide an opportunity for highly qualified, recent doctoral scientists to carry out an integrated program of independent research and education. Fellows may engage in observational, instrumental, theoretical, laboratory or archival data research in any area of astronomy or astrophysics, in combination with a coherent educational plan for the duration of the fellowship. The program supports researchers for a period of up to three years with fellowships that may be taken to eligible host institutions of their choice. The program is intended to recognize early-career investigators of significant potential and to provide them with experience in research and education that will establish them in positions of distinction and leadership in the scientific community.

Summary: The Translational Research Award (TRA) intends to accelerate the conversion of scientific findings into impactful clinical applications. The TRA prioritizes innovative approaches over purely iterative or incremental research. Submissions focusing on minor modifications to existing standards without the intent or potential to significantly improve clinical care or patient outcomes do not meet the intent of the mechanism.Distinctive Features: Basic research and clinical trials are prohibited. Preliminary data are required.·        For animal research, applications must describe the choice of model and its relevance to the human clinical condition.·        For research prospectively enrolling human subjects, the inclusion of community-based participatory research (CBPR) approaches is required.·        The Translational Research Award offers funding for two Research Levels. The applicant is responsible for selecting the Research Level based on the scope of the research.○       Research Level 1: Supports the refinement of mature ideas and concepts into tangible and knowledge products positioned for further evaluation.○       Research Level 2: Supports the rigorous evaluation of tangible and knowledge products in preparation for first-in-human studies or clinical trials.·        Early-Career Investigator Partnering Option (available for both Research Levels): This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award. 

Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Clinical Trial Award (CTA) intends to support clinical trials with the potential to have a significant impact on psychological health conditions and/or traumatic brain injury (TBI) through clinical applications, including health care products, technologies and/or practice guidelines.  Distinctive Features: Funding from this award mechanism must support a clinical trial.·        Clinical trials may be designed to evaluate a wide range of interventions, including new drugs, biologics, medical devices, diagnostics, therapies and behavioral health strategies.·        Preliminary data are required.·        The inclusion of community-based participatory research (CBPR) approaches is required.·        The CTA offers funding for two Research Levels. The applicant is responsible for selecting the Research Level based on the scope of the research.○       Research Level 1: Supports proof-of-principle pilot studies, as well as phase 1 and phase 2 clinical trials.○       Research Level 2: Supports larger-scale and advanced clinical trials that evaluate effectiveness in relevant patient populations.·        Early-Career Investigator Partnering Option (available for both Research Levels): This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award. 

Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Health Services Research Award (HSRA) intends to fund high-impact research that bridges the gap between research, practice and policy by building real-world evidence on how interventions, clinical practices/guidelines, or policies can be deployed to targeted populations at the appropriate time. In order to meet this intent, the mechanism supports health services research approaches. Distinctive Features: ·        The HSRA will support health services research approaches that include comparative effectiveness research; implementation of interventions, diagnostics and clinical practices/guidelines; and validation of data science insights. ·        Applications must include clinical research or clinical trials. Prospective or retrospective clinical research or clinical trials involving human subjects, human subject data/records, and human anatomical substances are allowed. ·        Preliminary data are required. ·        Basic, preclinical and animal research are prohibited. ·        For research prospectively enrolling human subjects, inclusion of community-based participatory research (CBPR) approaches is required. ·        Early-Career Investigator Partnering Option: This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award.

The goal of this NOFO is to support doctoral candidates studying high-priority areas of child health for the completion of their doctoral dissertation research project. This NOFO seeks to advance research in child health by stimulating the use of Environmental Influences on Child Health (ECHO) Cohort data by doctoral students in relevant scientific areas. This RFA will provide students working on dissertations the opportunity to access the ECHO data within the NICHD Data and Specimen Hub (DASH) repository. ECHO"s DASH dataset integrates de-identified longitudinal data from more than 71,000 participants across the U.S. Prenatal and child exposure data include physical, chemical, social, behavioral, and biological factors. ECHO"s five primary pediatric outcome areas are pre-, peri-, and postnatal outcomes, upper and lower airway, obesity, neurodevelopment, and positive health. This award will facilitate the entry of promising new investigators into the field of early environmental exposures and child health research, enhancing the pool of highly talented researchers.